RheumNow Week in Review – 21 October 2016
Dr. Cush Reviews Highlights from the past week on RheumNow.com. Register to receive free daily rheumatology news written by rheumatologists for rheumatologists. Download the podcast at iTunes.com.
Search for Terms or Answers
Dr. Cush Reviews Highlights from the past week on RheumNow.com. Register to receive free daily rheumatology news written by rheumatologists for rheumatologists. Download the podcast at iTunes.com.
Most women with systemic lupus erythematosus (SLE) have no or little disease activity during pregnancy, but experience greater disease activity or overt flares during the first year postpartum, a Norwegian study has found.
The Washington Post recently interviewed Dr. Eliza Chakavarty of the OMRF about the evolution in attitudes and outcomes of lupus women who wish to get pregnant.
The results of the Nor-Switch study were presented at the United European Gastroenterology annual congress this week demonstrating no significant difference in effect, adverse effects or antibody formation in patients switched from Remicade to the biosimilar infliximab (CT-P13, Remsima).
Pfizer has announced it will ship its new FDA-approved biosimilar, Inflectra, in late November and that it will be priced at a15 percent discount to current wholesale prices.
A Lancet meta-analysis has reviewed the preventative effects of low-molecular-weight heparin (LMWH) on placenta-mediated pregnancy complications include pre-eclampsia, late pregnancy loss, placental abruption, and birth of a small-for-gestational-age (SGA) neonate.
Dr Jack Cush reviews highlights from the news and journal articles appearing this week on RheumNow.com:
Rheumatologists have been challenged to treat hepatitis C virus (HCV)-induced rheumatic disease since discovery of the virus in 1989.
In this video, Michelle Petri, MD, director of the Hopkins Lupus Center at Johns Hopkins University, discusses recent successes and challenges in the treatment of systemic lupus erythematosus, with clinical trials results ranging from "wildly positive" to "completely negative."
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.